Innexus and Genhelix have signed a Letter of Intent to set the stage for a planned strategic collaboration, to focus on developing novel antibodies engineered with InNexus’ DXL technology.

The research and licensing agreement between the collaborators is expected to be complete later in 2009.

InNexus would conduct preclinical development for a DXL therapeutic against an undisclosed target, with Genhelix providing GMP production and commercial manufacturing.

InNexus CEO Jeff Morhet said that the organisations are poised to strategically collaborate as partners focused on the development of new products, while maintaining their respective business competencies.

“This collaboration provides significant opportunities for both companies, and represents a creative approach to partnering that brings resources and capabilities together while the partners stay focused,” Morhet said.

News of the planned alliance follows InNexus’ recently announced meeting with the US Food and Drug Administration (FDA).

The FDA expressed clear support for the company’s product development plans, following a comprehensive review of the proposed clinical pathway for its lead preclinical candidate, DXL625 (CD20).

The FDA also provided a manufacturing exception approval allowing InNexus to manufacture all clinical material needed for DXL625’s Phase I human trial.